跳至主要内容
临床试验/CTRI/2024/05/067130
CTRI/2024/05/067130尚未招募3 期

Comparative Effectiveness of Ayurveda (Ay) Intervention and Conventional Prophylaxis for Radiotherapy-Induced Oral Mucositis in patients undergoing Primary or Adjuvant Radiotherapy without Chemotherapy for Oral Cancers: A Prospective, Randomized, Open Label, Active-Controlled Pilot Study - COMPAIR

AyurVAID Hospitals0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.All oral cancer patients undergoing radiotherapy irrespective of type that are planned to be treated with primary or adjuvant Radiation Therapy using IMRT/3DCRT without chemotherapy.
  • 2. Treatment plan is to receive a continuous course of IMRT/3DCRT delivered as single daily fractions with a cumulative radiation dose of 60-70 Gy. Planned radiation treatment fields must include at least two oral sites (left and right buccal mucosa, floor of mouth, left and right ventral/lateral tongue, soft palate) that are each planned to receive a total of = 60 Gy.
  • 3. Age 18 years or older
  • 4. Eastern Cooperative Oncology Group (ECOG) performance status = 2
  • 5. Serum pregnancy test negative for females of childbearing potential
  • 6. Properly obtained written informed consent

排除标准

  • 1.Other Head and Neck Cancers, tumour of the larynx, hypopharynx, nasopharynx, sinuses, or salivary glands or past cancers with high risk of recurrence
  • 2. Prior radiotherapy to the region of the Research cancer or adjacent anatomical sites or more than 25% of total body marrow-bearing area (potentially interfering with chemo tolerance)
  • 3. Concurrent participation in another interventional clinical Research or use of another investigational agent within 30 days of the first dose of /Conventional care
  • 4. Inability to eat soft solid food at baseline for reasons other than mouth soreness after surgery or dental procedures
  • 5. Complete reliance on parenteral or gastrointestinal tube-delivered nutrition at baseline
  • 6. Active infectious disease or ulcerative lesions or infections in the oral cavity at baseline
  • 7. Presence of oral mucositis at baseline. (Subjects with mouth or throat pain solely due to post-operative effects are eligible.)
  • 8. Known history of human immunodeficiency virus (HIV) or history of active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
  • 9. Female patients who are pregnant or breastfeeding 10. Known allergies or intolerance to Ay/Conventional Care compounds

研究者

发起方
AyurVAID Hospitals

相似试验